Showing 11-20 of 827 results for "".
Biosimilars: What's Coming for Labeling?
https://practicaldermatology.com/topics/practice-management/biosimilars-whats-coming-for-labeling/20934/The public comment period on draft labeling guidance will end next month.2024 In Review: This Year's Trends in Dermatology
https://practicaldermatology.com/topics/feature/2024-review-years-trends-dermatology/29886/As the year comes to a close, Practical Dermatology asked Editorial Board members about trends from 2024—what was hot, what was not, new approvals that lived up to the hype, important new research, and other observations from the past year.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-11/23225/Primary Care Providers as Allies in Dermatology
https://practicaldermatology.com/topics/practice-management/primary-care-providers-as-allies-in-dermatology/21117/In light of a dermatology workforce shortage, PCPs see a majority of skin-related cases. Dermatologists can work with them to improve patient care.Biosimilars: Generic Biologics or Something Much More Complex?
https://practicaldermatology.com/topics/practice-management/biosimilars-generic-biologics-or-something-much-more-complex/21013/The looming availability of biosimilar medications raises important clinical and regulatory questions.What You Missed at San Diego Dermatology Symposium
https://practicaldermatology.com/topics/psoriasis/what-you-missed-at-san-diego-dermatology-symposium/19884/Jashin Wu, MD, founder of San Diego Dermatology Symposium, gives an overview of the 2020 meeting, which went virtual.Heart of the Matter: Effects of Psoriasis Treatment on CV Risks
https://practicaldermatology.com/topics/psoriasis/heart-of-the-matter-effects-of-psoriasis-treatment-on-cv-risks/18747/By Jashin Wu, MD and Seemal R. Desai, MDThere's growing evidence that treatment of psoriasis reduces the risk of CV events, but it's not clear whether this potential benefit should influence treatment decisions. Patient screening and counseling remain important, Dr. Wu says.Psoriasis and Inflammatory Disease Management Today
https://practicaldermatology.com/topics/psoriasis/psoriasis-and-inflammatory-disease-management-today/19885/COVID-19 can have implications for psoriasis management. Jashin Wu, MD, founder of San Diego Dermatology Symposium, provides guidance on management and introduces the Inaugural Symposium for Inflammatory Skin Disease, coming virtually in April.The Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market availPapa in at Valeant, J&J Acquires Neostrata, Celebrity Lip Envy
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-papa-in-at-valeant-j-j-acquires-neostrata-celebrity-lip-envy/18772/This edition of DermWireTV brings news that Joseph C. Papa has left Perrigo Company plc, a top five global over-the-counter consumer goods and pharmaceutical company, to take the helm as CEO at Valeant Pharmaceuticals. He will replace J. Micheal Pearson. Valeant also concluded its investigation arou